Kingston, Canada

Damian P Redfearn

This inventor holds 3 USPTO granted patents and 2 published patent applications, plus 2 CIPO patents. Top assignees: Kingston Health Sciences Centre, Queen's University at Kingston. Active years: 2022-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Damian P Redfearn. Retrieved from https://idiyas.com/inventor/damian-p-redfearn

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 3 

% Patents Active = 100.0

 

Average Co-Inventor Count = 2.3

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2022-2024

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Damian P Redfearn

Introduction

Damian P Redfearn is a notable inventor based in Kingston, Canada. He has made significant contributions to the field of cardiac health through his innovative patents. With a total of 3 patents, Redfearn's work focuses on advanced methods for diagnosing and treating cardiac arrhythmias.

Latest Patents

One of his latest patents is titled "Sequential mapping of cardiac arrhythmia without fiducial time reference." This method generates propagation and velocity maps for cardiac wavefront propagation, including various rhythms such as cardiac arrhythmia, sinus rhythm, and paced rhythm. The technique allows for activation time information to be generated without any time alignment reference, utilizing a weighted summation of candidate functions selected from a bank of functions. This innovation is applicable to both single catheter mapping and sequential mapping, proving robust in generating propagation maps and conduction velocity even amidst multiple colliding wavefronts. These maps are crucial for diagnosing and localizing cardiac arrhythmia, as well as guiding catheter ablation and pacing therapies.

Another significant patent by Redfearn is "Long QT syndrome diagnosis and classification." This method involves obtaining data from a subject's electrocardiogram (ECG) signal and identifying features based on selected inflection points. By categorizing segments of the ECG signal, the method classifies the signal as normal or indicative of long QT syndrome. Furthermore, it can determine whether the long QT syndrome is of Type 1 or Type 2.

Career Highlights

Throughout his career, Redfearn has worked with esteemed institutions such as Queen's University at Kingston and Kingston Health Sciences Centre. His contributions to these organizations have been instrumental in advancing cardiac health research and technology.

Collaborations

Redfearn has collaborated with notable colleagues, including Mohammad Hassan Shariat and Habib Hajimolahoseini. Their combined expertise has further enriched the research and development of innovative cardiac solutions.

Conclusion

Damian P Redfearn's work exemplifies the impact of innovation in the medical field, particularly in cardiac health. His patents not only enhance diagnostic capabilities but also improve treatment methodologies for cardiac arrhythmias.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…